Theralase Technologies Inc. V.TLT

RE:RE:The best competition has to offer

[CancerSlayer]

CancerSlayer wrote:

enriquesuave wrote:

72% CR and 59% durable CR response at 12 months or better. Combination of N-803 with BCG. Combination drugs offer uneven comparison but gives us an idea of the most competitive treatment modality. This is still many more treatments using standard BCG protocol plus N-803 so about 12-15 treatments or more and has more side effects. But still very good outcome. If we match or beat their numbers we will shine as the next gold standard. Imo. Much more patient friendly just can't afford any screw ups. 

https://immunitybio.com/category/press-releases/

 

 

 

Those are impactful %s and agree...this is our biggest competitor.  Just want to clarify the 59% reported was the "percentage probability" of maintaining a CR at 12 months.  This percentage would actually equate to a 42% durable CR at 12 months.  Still commendable, but makes for a more conquerable target.  Also, I believe the total number of treatments could even exceed "20" over 18 months in certain patients per their trial protocol.  

If we accomplish similar efficacy (a realistic possibility & could even exceed), we should still be in the driver seat when considering the ease/simplicity of our "two" treatments, safety profile & treatment cost.  

There were 51 responders out of a total of 71 evaluable patients & a reported 59% probability those 51 responders would maintain a durable CR.  This would be 0.59 X 51 = 30 patients.  30 of 71 total evaluable patients = 42% durable response at 12 months.